leuprolide

(redirected from Eligard)
Also found in: Dictionary.
Related to Eligard: Lupron

leuprolide

 [loo-pro´līd]
a synthetic analogue of gonadotropin-releasing hormone, used in the form of the acetate ester as an antineoplastic agent, treatment for endometriosis, and gonadotropin inhibitor. Administered subcutaneously or intramuscularly.

leuprolide

/leu·pro·lide/ (loo-pro´līd) a synthetic analogue of gonadotropin-releasing hormone, used in the form of the acetate ester as an antiendometriotic agent, antineoplastic, and gonadotropin inhibitor.

leuprolide

(lo͞o′prō-līd′)
n.
A drug that is a synthetic polypeptide analog of naturally occurring gonadotropin-releasing hormone, C29H84N16O12, used in its acetate form to treat advanced prostate cancer.

leuprolide

Viadur® An analogue of gonadotropin-releasing hormone, which has been used to manage PMS, and block ovarian or testicular hormone production in Pts with hormonally active CA. See PMS.
References in periodicals archive ?
ELIGARD, which is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer, is developed and manufactured by the company.
Atrix will receive royalty payments based on sales of the Eligard products upon approval.
M2 EQUITYBITES-May 10, 2016-TOLMAR Pharmaceuticals receives FDA label update approval for ELIGARD prostate cancer drug
M2 PHARMA-May 10, 2016-TOLMAR Pharmaceuticals receives FDA label update approval for ELIGARD prostate cancer drug
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact [sanofi-aventis, Laval, QC], Eligard [sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc.
The FDA has not made any conclusions about whether diabetes or these cardiovascular diseases are caused by treatment with these drugs, which are available in generic formulations and as brand-name products (Lupron, Eligard, Synarel, Trelstar, Vantas, Viadur, and Zoladex).
For example, QLT competes in the ocular market with Visudyne for age-related macular degeneration, while Atrix is a strong player in oncology with its Eligard, a drug aimed at combating prostate cancer.
In December 2001, Atrix's European marketing partner, MediGene AG, submitted a Marketing Authorization Application (MAA) for Eligard 7.
Fort Collins, CO) announced that the United States Patent and Trademark Office issued United States Patent 6,565,874, which effectively extends patent protection for the prostate cancer products franchise, Eligard (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer, to 2018.
Atrix says competing products Lupron and Zoladex are delivered via intra-muscular injection, whereas its Eligard is delivered just beneath the skin.
M2 EQUITYBITES-May 6, 2016-TOLMAR Pharmaceuticals wins US FDA approval for ELIGARD storage at room temperature
M2 PHARMA-May 6, 2016-TOLMAR Pharmaceuticals wins US FDA approval for ELIGARD storage at room temperature